2023 Year End Lab Report

In the past year we have been working with mice that have tumors induced by exposure to a chemical that causes cancer to develop from single cells, as it does in humans. Using this model will ensure a more successful transfer of our therapy to clinical human trials.

We are currently working to accomplish consistent comprehensive secretion of anticancer immune stimulating proteins from our bacteria into tumors in every mouse administered our therapy. These experiments involve adjusting levels and timing of dosing and comparing different methods of protein secretion from the bacteria.

We are also undertaking experiments to observe changes in immune cells in tumors in response to our therapy. The results of these experiments will indicate the combination of immune modulating proteins to be genetically engineered into our bacteria to optimize the anticancer immune response produced by this therapy.  

Lance B. Augustin, Ph.D.